









Markets
/
Stocks
/
nasdaq-tnfa
/

TNF Pharmaceuticals Inc

TNFA

3.860USD

-0.040-1.03%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

113.42MMarket Cap

LossP/E TTM



TNF Pharmaceuticals Inc

3.860

-0.040-1.03%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

249 / 506

Overall Ranking

407 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel therapies for age-related diseases and autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Supera-CBD is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the growing CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not currently regulated as drugs.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 78.72.

Undervalued

The company’s latest PE is -1.92, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 215.39K shares, decreasing 80.94% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 140.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 8.19.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.02, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.02

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.94, which is -97.00% below the recent high of -0.06 and 89.22% above the recent low of -0.21.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 249/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.49, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 5.92 and the support level at 0.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.49

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.053

Buy

RSI(14)

76.472

Buy

STOCH(KDJ)(9,3,3)

57.823

Neutral

ATR(14)

0.715

Low Volatility

CCI(14)

32.892

Neutral

Williams %R

64.773

Sell

TRIX(12,20)

10.468

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.914

Sell

MA10

3.849

Buy

MA20

2.654

Buy

MA50

1.126

Buy

MA100

0.644

Buy

MA200

0.687

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 1.52%, representing a quarter-over-quarter decrease of 87.31%. The largest institutional shareholder is The Vanguard, holding a total of 140.00 shares, representing 0.01% of shares outstanding, with 98.50% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Morgan Stanley Smith Barney LLC

102.03K

+61.49%

CreativeOne Wealth, LLC

23.00K

Geode Capital Management, L.L.C.

28.05K

+69.28%

Key Client Fiduciary Advisors, LLC

20.00K

The Vanguard Group, Inc.

Star Investors

14.00K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.93, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.